Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MALMOREDE vs ARALEN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Hepatocellular carcinoma (HCC) as an adjunct to transcatheter arterial chemoembolization (TACE) in China,Malignant melanoma (adjuvant therapy, limited approval in certain regions),Non-small cell lung cancer (combination therapy, clinical trials)
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
4-6 hours; increased in renal impairment (up to 12-15 hours).
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Primarily metabolized by peptidases in plasma and tissues; not significantly metabolized by hepatic CYP450 enzymes.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Primarily renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
80-85% bound, primarily to albumin.
50-60%, primarily to albumin and α1-acid glycoprotein.
1.2-1.5 L/kg (30-40 L in 70 kg adult); suggests moderate tissue distribution.
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
Oral: 60-70% (first-pass effect); IM: 90-100%.
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
Cr Cl 30-50 m L/min: 50 mg once daily; Cr Cl 15-29 m L/min: 50 mg every 48 hours; Cr Cl <15 m L/min or on dialysis: not recommended.
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily; Child-Pugh C: not recommended.
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
Weight <20 kg: not established; 20-40 kg: 2.5 mg/kg/day divided q12h; >40 kg: adult dosing.
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
Start at lowest effective dose (25 mg daily) due to increased sensitivity; monitor renal function.
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
None
No FDA black box warning.
May cause injection site reactions, transient fever, and mild fatigue. Caution in patients with autoimmune disorders or severe hepatic impairment. Monitor liver function periodically.
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hypersensitivity to malmorede or any excipients; patients with severe autoimmune diseases such as active lupus erythematosus or multiple sclerosis.
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
Avoid grapefruit, grapefruit juice, Seville oranges, and pomelos due to CYP3A4 inhibition. High-fat meals may reduce absorption; take on an empty stomach (1 hour before or 2 hours after a meal). Limit alcohol intake as it may increase hepatotoxicity risk.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
Malmorede has no reported human data. Animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; Second trimester: no known risk; Third trimester: no known risk. FDA pregnancy category N (not classified).
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
Unknown if excreted in human milk. M/P ratio not determined. Use with caution; consider benefits versus potential risks to infant.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
No dosage adjustment required based on pharmacokinetic changes in pregnancy due to lack of data.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
MALMOREDE is a novel oral antineoplastic agent with a complex pharmacokinetic profile; its absorption is significantly affected by gastric p H, so avoid concurrent use of proton pump inhibitors (PPIs) and H2 receptor antagonists. Monitor for QT prolongation; obtain baseline ECG and electrolytes. Hepatic metabolism via CYP3A4 necessitates caution with strong inhibitors/inducers. Dose adjustment required in moderate-severe hepatic impairment.
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
Take this medication at the same time each day with a full glass of water.,Do not take with grapefruit or grapefruit juice; avoid Seville oranges and pomelos.,Swallow capsules whole; do not crush, chew, or open.,If you miss a dose, skip it if within 12 hours of next dose; do not double up.,Report any new or worsening chest pain, palpitations, or fainting immediately.,Use effective contraception during treatment and for 3 months after last dose.,Avoid alcohol and limit consumption of high-fat meals as they may alter drug absorption.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MALMOREDE vs ARALEN HYDROCHLORIDE, answered by our medical review team.
MALMOREDE is a Antimalarial that works by Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.. ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MALMOREDE and ARALEN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MALMOREDE is: Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.. The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MALMOREDE and ARALEN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MALMOREDE is classified as Category C. Malmorede has no reported human data. Animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; Second trimester: no known risk; Thir. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.